Literature DB >> 15885118

Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade.

S D Allen1, S V Rawale, C C Whitacre, P T P Kaumaya.   

Abstract

Cognate interactions between immune effector cells and antigen-presenting cells (APCs) govern immune responses. Specific signals occur between the T-cell receptor peptide and APCs and nonspecific signals between pairs of costimulatory molecules. Costimulation signals are required for full T-cell activation and are assumed to regulate T-cell responses as well as other aspects of the immune system. As new discoveries are made, it is becoming clear how important these costimulation interactions are for immune responses. Costimulation requirements for T-cell regulation have been extensively studied as a way to control many autoimmune diseases and downregulate inflammatory reactions. The CD28:B7 and the CD40:CD40L families of molecules are considered to be critical costimulatory molecules and have been studied extensively. Blocking the interaction between these molecules results in a state of immune unresponsiveness termed 'anergy'. Several different strategies for blockade of these interactions are explored including monoclonal antibodies (mAbs), Fab fragments, chimeric, and/or fusion proteins. We developed novel, immune-specific approaches that interfere with these interactions. Using experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis mediated by central nervous system (CNS)-specific T-cells, we developed a multi-targeted approach that utilizes peptides for blockade of costimulatory molecules. We designed blocking peptide mimics that retain the functional binding area of the parent protein while reducing the overall size and are thus capable of blocking signal transduction. In this paper, we review the role of costimulatory molecules in autoimmune diseases, two of the most well-studied costimulatory pathways (CD28/CTLA-4:B7 and CD40:CD40L), and the advantages of peptidomimetic approaches. We present data showing the ability of peptide mimics of costimulatory molecules to suppress autoimmune disease and propose a mechanism for disease suppression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15885118     DOI: 10.1111/j.1399-3011.2005.00256.x

Source DB:  PubMed          Journal:  J Pept Res        ISSN: 1397-002X


  19 in total

1.  Past, present, and future prospects for inducing donor-specific transplantation tolerance for composite tissue allotransplantation.

Authors:  Larry D Bozulic; Warren C Breidenbach; Suzanne T Ildstad
Journal:  Semin Plast Surg       Date:  2007-11       Impact factor: 2.314

Review 2.  Targeted delivery with peptidomimetic conjugated self-assembled nanoparticles.

Authors:  Esmaiel Jabbari
Journal:  Pharm Res       Date:  2008-12-17       Impact factor: 4.200

3.  Small-molecule costimulatory blockade: organic dye inhibitors of the CD40-CD154 interaction.

Authors:  Emilio Margolles-Clark; Oliver Umland; Norma S Kenyon; Camillo Ricordi; Peter Buchwald
Journal:  J Mol Med (Berl)       Date:  2009-08-26       Impact factor: 4.599

Review 4.  Peptides and peptidomimetics as immunomodulators.

Authors:  Ameya S Gokhale; Seetharama Satyanarayanajois
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

5.  HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells.

Authors:  Megan Jo Miller; Kevin C Foy; Jay P Overholser; Rita Nahta; Pravin Tp Kaumaya
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

6.  IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides.

Authors:  Kevin Chu Foy; Megan J Miller; Jay Overholser; Siobhan M Donnelly; Rita Nahta; Pravin Tp Kaumaya
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

Review 7.  Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.

Authors:  Pravin T P Kaumaya; Kevin Chu Foy
Journal:  Future Oncol       Date:  2012-08       Impact factor: 3.404

8.  Inhibition of CD40-CD154 costimulatory pathway by a cyclic peptide targeting CD154.

Authors:  Ilaria Deambrosis; Sara Lamorte; Fulvia Giaretta; Lorenzo Tei; Luigi Biancone; Benedetta Bussolati; Giovanni Camussi
Journal:  J Mol Med (Berl)       Date:  2008-11-05       Impact factor: 4.599

Review 9.  Role of platelets in neuroinflammation: a wide-angle perspective.

Authors:  Lawrence L Horstman; Wenche Jy; Yeon S Ahn; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; J Steven Alexander; Alireza Minagar
Journal:  J Neuroinflammation       Date:  2010-02-03       Impact factor: 8.322

10.  A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice.

Authors:  Gisela M Vaitaitis; Michael H Olmstead; Dan M Waid; Jessica R Carter; David H Wagner
Journal:  Diabetologia       Date:  2014-08-08       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.